{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T21:30:20Z","timestamp":1773696620407,"version":"3.50.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1A5A2015369, 2018R1C1B6005036"],"award-info":[{"award-number":["2017R1A5A2015369, 2018R1C1B6005036"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Mitochondrial dysfunction with oxidative stress contributes to nonalcoholic fatty liver disease (NAFLD) progression. We investigated the steatosis predictive efficacy of a novel non-invasive diagnostic panel using metabolic stress biomarkers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Altogether, 343 subjects who underwent magnetic resonance imaging-based liver examinations from a population-based general cohort, and 41 patients enrolled in a biopsy-evaluated NAFLD cohort, participated in the development and validation groups, respectively. Serologic stress biomarkers were quantitated by enzyme-linked immunosorbent assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Multivariate regression showed that waist-to-hip ratio, fibroblast growth factor (FGF) 21, FGF19, adiponectin-to-leptin ratio, insulin, albumin, triglyceride, total-cholesterol, and alanine-aminotransferase were independent predictors of steatosis (rank-ordered by Wald). The area under receiver-operator characteristics curve [AUROC (95%CI)] of the metabolic stress index for steatosis (MSI-S) was 0.886 (0.85\u22120.92) and 0.825 (0.69\u22120.96) in development and validation groups, respectively. MSI-S had higher diagnostic accuracy (78.1%\u221281.1%) than other steatosis indices. MSI-S notably differentiated steatosis severities, while other indices showed less discrimination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MSI-S, as a novel non-invasive index, based on mitochondrial stress biomarker FGF21 effectively predicted steatosis. Furthermore, MSI-S may increase the population that could be excluded from further evaluation, reducing unnecessary invasive investigations more effectively than other indices.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.896334","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T05:55:27Z","timestamp":1652939727000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Metabolic Stress Index Including Mitochondrial Biomarker for Noninvasive Diagnosis of Hepatic Steatosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Jae Seung","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jhii-Hyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Hee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Baek","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jang-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Koo","family":"Baik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Hye","family":"Huh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu-Sang","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23594","article-title":"Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection","volume":"51","author":"Starley","year":"2010","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1204265","article-title":"Human Fatty Liver Disease: Old Questions and New Insights","volume":"332","author":"Cohen","year":"2011","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive Biomarkers in NAFLD and NASH - Current Progress and Future Promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.025","article-title":"Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis by Combined Serum Biomarkers","volume":"56","author":"Shen","year":"2012","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.02.014","article-title":"Molecular Mechanisms of Lipotoxicity and Glucotoxicity in Nonalcoholic Fatty Liver Disease","volume":"65","author":"Mota","year":"2016","journal-title":"Metabolism"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.06.083","article-title":"Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases","volume":"155","author":"Mansouri","year":"2018","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1038\/emm.2016.157","article-title":"Oxidative Stress and Calcium Dysregulation by Palmitate in Type 2 Diabetes","volume":"49","author":"Ly","year":"2017","journal-title":"Exp Mol Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.066","article-title":"Pathogenesis of Nonalcoholic Steatohepatitis","volume":"150","author":"Machado","year":"2016","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2016.11.006","article-title":"Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies","volume":"28","author":"Sunny","year":"2017","journal-title":"Trends Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cellsig.2017.08.009","article-title":"Integrated Stress Response Stimulates FGF21 Expression: Systemic Enhancer of Longevity","volume":"40","author":"Salminen","year":"2017","journal-title":"Cell Signal"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201702058","article-title":"Multi-Omics Analysis Identifies ATF4 as a Key Regulator of the Mitochondrial Stress Response in Mammals","volume":"216","author":"Quiros","year":"2017","journal-title":"J Cell Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3475-6","article-title":"Fibroblast Growth Factor 21 Participates in Adaptation to Endoplasmic Reticulum Stress and Attenuates Obesity-Induced Hepatic Metabolic Stress","volume":"58","author":"Kim","year":"2015","journal-title":"Diabetologia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/ggi.12724","article-title":"Secreted Growth Differentiation Factor 15 as a Potential Biomarker for Mitochondrial Dysfunctions in Aging and Age-Related Disorders","author":"Fujita","year":"2016","journal-title":"Geriatr Gerontol Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201642195","article-title":"The Integrated Stress Response","volume":"17","author":"Pakos-Zebrucka","year":"2016","journal-title":"EMBO Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2015.04.004","article-title":"Adaptation of Hepatic Mitochondrial Function in Humans With Non-Alcoholic Fatty Liver is Lost in Steatohepatitis","volume":"21","author":"Koliaki","year":"2015","journal-title":"Cell Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0684","article-title":"Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance","volume":"32","author":"Chavez","year":"2009","journal-title":"Diabetes Care"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18052242","article-title":"Effects of Exercise Intervention on Mitochondrial Stress Biomarkers in Metabolic Syndrome Patients: A Randomized Controlled Trial","volume":"18","author":"Chang","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2015.00147","article-title":"Research Perspectives on the Regulation and Physiological Functions of FGF21 and Its Association With NAFLD","volume":"6","author":"Inagaki","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2008.06.014","article-title":"The Circulating Metabolic Regulator FGF21 Is Induced by Prolonged Fasting and PPARalpha Activation in Man","volume":"8","author":"Galman","year":"2008","journal-title":"Cell Metab"},{"key":"B20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4093\/dmj.2012.36.1.29","article-title":"Various Oscillation Patterns of Serum Fibroblast Growth Factor 21 Concentrations in Healthy Volunteers","volume":"36","author":"Lee","year":"2012","journal-title":"Diabetes Metab J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0223","article-title":"Prospective Study of Serum Adiponectin and Incident Metabolic Syndrome: The ARIRANG Study","volume":"36","author":"Kim","year":"2013","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.12120896","article-title":"Nonalcoholic Fatty Liver Disease: MR Imaging of Liver Proton Density Fat Fraction to Assess Hepatic Steatosis","volume":"267","author":"Tang","year":"2013","journal-title":"Radiology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.06.005","article-title":"Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis","volume":"153","author":"Middleton","year":"2017","journal-title":"Gastroenterology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20701","article-title":"Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2012.03.019","article-title":"Preliminary Evidence of a Reduced Serum Level of Fibroblast Growth Factor 19 in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease","volume":"45","author":"Eren","year":"2012","journal-title":"Clin Biochem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2009.02022.x","article-title":"Serum Adipokine Levels Predictive of Liver Injury in Non-Alcoholic Fatty Liver Disease","volume":"29","author":"Lemoine","year":"2009","journal-title":"Liver Int"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2012-0253","article-title":"A Decrease in Fasting FGF19 Levels is Associated With the Development of Non-Alcoholic Fatty Liver Disease in Obese Adolescents","volume":"25","author":"Wojcik","year":"2012","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2010.09.003","article-title":"Serum Total Adiponectin in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"60","author":"Polyzos","year":"2011","journal-title":"Metabolism"},{"key":"B29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00125-015-3769-3","article-title":"Circulating Leptin in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"59","author":"Polyzos","year":"2016","journal-title":"Diabetologia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01774.x","article-title":"Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis","volume":"103","author":"Wieckowska","year":"2008","journal-title":"Am J Gastroenterol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.896334\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T05:55:33Z","timestamp":1652939733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.896334\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":30,"alternative-id":["10.3389\/fendo.2022.896334"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.896334","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"article-number":"896334"}}